abstract |
The subject invention is directed to a VEGFR2 (vascular endothelial growth factor receptor II) monoclonal antibody (mAb), and the amino acid sequence of the heavy chain and the light chain of the mAb. The invention is also directed to methods for making the VEGFR2 mAb, and methods of using the mAb to inhibit angiogenesis and treat various conditions such as tumor and retinal diseases. |